Profile cover photo
Profile photo
Oncodesign SA
1 follower -
Oncodesign is a leading biopharmaceutical company
Oncodesign is a leading biopharmaceutical company

1 follower
About
Posts

Post has attachment
[Press Release] Oncodesign reports positive results for its MNK1/2 program - Cancer

MNK1 and MNK2 are kinases targeted in a major activation pathway for several cancers

“Following on from the ALK1 program, MNK1/2 is the second to commence lead optimization in a very short period of time thanks to the expertise and additional resources invested in our drug discovery programs since we integrated the François Hyafil research center’s capabilities”, commented Jan Hoflack, Oncodesign’s Chief Scientific Officer and Chief Operating Officer. “

Read Press Release http://bit.ly/2AxsJ7n
Photo
Add a comment...

Post has attachment
[Job offer] Oncodesign is looking for a Scientific Data IT Engineer for Oncodesign SA located in France.
Visit our website for downloading job offer.
http://bit.ly/2zQ54Sj
Add a comment...

Post has attachment
[Job offer] Oncodesign is looking for an Operations Director for its subsidiary located in the US.
Visit our website for downloading job offer.
http://bit.ly/2zQ54Sj
Add a comment...

Post has attachment
[Poster] Widespread Brain Distribution Of Sgsh Enzyme In Canine Brain Following White Matter Injection Of Lys-Saf302, An Aavrh.10-Sgsh Vector

Download our Poster on orphan disease on MPS!

http://bit.ly/2jOAYay
Add a comment...

Post has attachment
[Seminar] To know all about PDX: 23rd November

For the 2nd year, the IMODI consortium is organizing its 1-day seminar to present the breakthroughs and outcomes regarding PDX.

Follow us to get the opportunity to receive the resume of the day!
Or contact Florence Fombertasse for any further information: florence.fombertasse@Oncodesign.com
Photo
Add a comment...

Post has attachment
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. 

Read full article in AACR journal
http://cancerres.aacrjournals.org/content/77/21/e62
Add a comment...

Post has attachment
Oncodesign announces positive results opening the way for the ALK1 program to advance to the lead optimization phase.

“At the end of the Lead Optimization phase a drug candidate could be selected for preclinical trials & then clinical development”, said Jan Hoflack, Oncodesign’s Chief Scientific & Operating Officer.

Read Press Release
https://www.oncodesign.com/en/news-oncodesign/800-oncodesign-announces-positive-results-opening-the-way-for-the-alk1-program-to-advance-to-the-lead-optimization-phase
Photo
Add a comment...

Post has attachment
Unique Bioanalysis integrated platform

Oncodesign will focus on its solution: its unique BioAnalysis' integrated platform. We can thus propose you customised solutions throughout your drug development process & whatever your molecule is
http://bcn.europeanbioanalysisforum.eu/
Add a comment...

Post has attachment
3rd Annual Summit ICI -14-16 November – Munich
Join this unique event where experts in ICI drugs gather to disclose and discuss the latest outcomes regarding immuno-oncology. Oncodesign will be part of this event amongst key leader opinions and scientists.
See you there!
http://immunecheckpoint-europe.com
Add a comment...

Post has attachment
Don’t miss our posters during the EORTC congress - Sunday Oct 29, 2017 – Hall E
Come and see Emily & Marc during the poster session to know more about our outstanding breakthrough regarding breast cancer treatment.
1/ Synergistic anticancer activity of eribulin plus palbociclib in patient-derived xenograft (PDX) models of ER+/Her2- human breast cancer
– Poster B191

2/ Anti-tumour activity of new antibody drug conjugate (ADC) with eribulin in triple negative breast cancer (TNBC) patient-derived xenograft (PDX) - Poster B107
https://lnkd.in/dEvsN6D
Photo
Add a comment...
Wait while more posts are being loaded